Laidlaw's James Ahern Named to Crain's New York Notable Leaders in Finance 2024

2024-03-26

高管变更

NEW YORK, March 26, 2024 /PRNewswire/ -- Laidlaw & Co. Managing Partner James Ahern has been named one of Crain's New York's Notable Leaders in Finance for 2024. Mr. Ahern has been at Laidlaw for fourteen years and is credited with the firm's strategic investments in some of the most promising and cutting-edge healthcare advancements to date.

Mr. Ahern's main responsibilities at the firm are centered around venture capital investments, where approximately $300 million has been deployed, creating billions in public market value.

"Jimmy is one of the brightest, most intuitive investors I know," said Laidlaw's Chief Executive Officer Matthew Eitner. "He has his pulse on the future of healthcare."

Mr. Ahern funded and brought Actinium Pharmaceuticals public, putting a total of $61 million into the company. This success led to him to founding Relmada Therapeutics, with Laidlaw investing the first $52 million. As a result, that company grew to be worth more than a billion dollars in market value.

Mr. Ahern said, "I would like to thank Crain's and everyone at Laidlaw. It is truly an honor to be named amongst so many entrepreneurs in New York's financial sector."

Mr. Ahern currently serves on the board of directors of venture companies Algorithm Sciences, Aerwave Medical Technologies, Voltron Therapeutics, and PD Theranostics, Inc. He is on the board of the New York City Renaissance, one of the nation's top Amateur Athletic Union (AAU) basketball programs. He also serves on the board of overseers for the Big Brothers Big Sisters of Eastern Massachusetts.

About Laidlaw & Co.

For nearly two centuries, Laidlaw & Company has maintained a legacy of independent investment banking and securities brokerage, tailored to the specific needs of both domestic and international companies, corporate entrepreneurs, institutions, and private clients worldwide.

Our expansive and continually growing network spans across the United States and Europe. These professionals operate under our FINRA registered subsidiary and extend our influence through an FCA authorized subsidiary based in London.

Additionally, our team in healthcare-focused investment banking and capital markets comprises mainly senior professionals. These experts seamlessly merge 'bulge' bracket experience with the unique perspective of an entrepreneurial 'independent' firm. Their primary objective is to offer in-depth, hands-on transaction management and holistic solutions. One of our distinctive capabilities lies in aiding emerging companies to swiftly secure capital, courtesy of our robust retail sales force. This ensures our corporate clients enjoy the financial latitude they need to thrive and expand.

At our core, we foster an entrepreneurial spirit, marked by a robust work ethic and an innovative "think outside the box" approach. We specialize in gathering assets and delivering financial solutions through both our in-house and independent sales offices.

Contact: Chris Bastardi

[email protected]

SOURCE Laidlaw and Company

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构